The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2024 | AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti, MD, Humanitas Research Hospital, Milan, Italy, presents the findings of a single-center retrospective study that compared the outcomes of allogeneic stem cell transplantation (alloSCT) following immunotherapy or drug-conjugated antibody to those following standard chemotherapy in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). In previous literature, immunotherapy approaches, such as immune checkpoint inhibitors, prior to alloSCT were associated with an increased rate of toxicity and acute graft-versus-host-disease (GvHD). However, in this retrospective analysis, no differences in toxicity or non-relapse mortality were observed between cohorts. Dr Mariotti highlights that the reduced incidence of relapse and improved survival outcomes in the immunotherapy cohort suggest that this approach may lead to better disease control. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
